Internal Medicine and Rehabilitation Unit, Department of Internal Medicine, Rehabilitation and Geriatrics, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Infectious and Tropical Disease Unit, Lyon-1 University, Centre International de Recherche en Infectiologie, Centre CNRS U1111 (INSERM)-UMR5308, ENS de Lyon, UCBL1, Lyon, France.
Eur J Clin Microbiol Infect Dis. 2017 Sep;36(9):1577-1585. doi: 10.1007/s10096-017-2971-2. Epub 2017 Apr 4.
During prosthetic joint infection (PJI), optimal surgical management with exchange of the device is sometimes impossible, especially in the elderly population. Thus, prolonged suppressive antibiotic therapy (PSAT) is the only option to prevent acute sepsis, but little is known about this strategy. We aimed to describe the characteristics, outcome and tolerance of PSAT in elderly patients with PJI. We performed a national cross-sectional cohort study of patients >75 years old and treated with PSAT for PJI. We evaluated the occurrence of events, which were defined as: (i) local or systemic progression of the infection (failure), (ii) death and (iii) discontinuation or switch of PSAT. A total of 136 patients were included, with a median age of 83 years [interquartile range (IQR) 81-88]. The predominant pathogen involved was Staphylococcus (62.1%) (Staphylococcus aureus in 41.7%). A single antimicrobial drug was prescribed in 96 cases (70.6%). There were 46 (33.8%) patients with an event: 25 (18%) with an adverse drug reaction leading to definitive discontinuation or switch of PSAT, 8 (5.9%) with progression of sepsis and 13 died (9.6%). Among patients under follow-up, the survival rate without an event at 2 years was 61% [95% confidence interval (CI): 51;74]. In the multivariate Cox analysis, patients with higher World Health Organization (WHO) score had an increased risk of an event [hazard ratio (HR) = 1.5, p = 0.014], whereas patients treated with beta-lactams are associated with less risk of events occurring (HR = 0.5, p = 0.048). In our cohort, PSAT could be an effective and safe option for PJI in the elderly.
在人工关节感染(PJI)中,有时不可能进行最佳的手术治疗(即用置换装置来更换感染的关节),尤其是在老年人群中。因此,延长抗生素抑制治疗(PSAT)是预防急性败血症的唯一选择,但对于这种策略知之甚少。我们旨在描述 PJI 老年患者接受 PSAT 的特征、结果和耐受性。我们进行了一项全国性的、年龄在 75 岁以上的 PJI 患者接受 PSAT 治疗的病例交叉队列研究。我们评估了事件的发生情况,这些事件定义为:(i)感染局部或全身进展(失败),(ii)死亡,(iii)PSAT 停药或换药。共纳入 136 例患者,中位年龄为 83 岁[四分位距(IQR)81-88]。主要病原体为葡萄球菌(62.1%)(金黄色葡萄球菌占 41.7%)。96 例(70.6%)患者使用了单一抗菌药物。有 46 例(33.8%)患者发生了事件:25 例(18%)因药物不良反应导致 PSAT 停药或换药,8 例(5.9%)因败血症进展,13 例死亡(9.6%)。在接受随访的患者中,2 年时无事件生存率为 61%[95%置信区间(CI):51%;74%]。在多变量 Cox 分析中,WHO 评分较高的患者发生事件的风险增加[风险比(HR)=1.5,p=0.014],而接受β-内酰胺治疗的患者发生事件的风险较低(HR=0.5,p=0.048)。在我们的队列中,PSAT 可能是老年 PJI 的一种有效且安全的选择。